TLC-2716

Overview

TLC-2716 is an orally available, gut- and liver-restricted inhibitor against LXRα and LXRβ , with EC 50 values of 7 nM and 15 nM, respectively. TLC-2716 represses LXRα/β transcriptional activity, downregulates genes involved in lipogenesis, lipid absorption and lipoprotein metabolism, and preserves peripheral reverse cholesterol transport. TLC-2716 reduces lipid accumulation, suppresses inflammation and fibrotic gene expression, enhances triglyceride-rich lipoprotein clearance, and improves glucose homeostasis and insulin sensitivity. TLC-2716 lowers serum and hepatic triglycerides, plasma cholesterol and other atherogenic lipid profiles in experimental models and humanized liver mice. TLC-2716 can be used for the research of dyslipidemia and related cardiometabolic disorders.

Application

Products | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Cardiovascular Disease | Products > Disease Areas > Lipid Metabolism | Products > Disease Areas > Atherosclerosis | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Vitamin D Related/Nuclear Receptor | Products > Research Areas > Metabolic Disease | Products > Research Areas > Cardiovascular Disease | Products > Signaling Pathways > LXR

Product Information

• Catalog No.: HY-182014
• CAS No.: 2408041-54-1
• Molecular Formula: C38H22ClF3N4O5S
• Molecular Weight: 739.12
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.
• Availability: In-stock

Source

Original product source